Notice of Proposed Sale · 144
Ocular Therapeutix, Inc.
OCULNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- OCULAR THERAPEUTIX, INC.
- Issuer CIK
- 0001393434
- SEC file number
- 001-36554
- Phone
- 781-357-4000
- Person for whose account securities are to be sold
- JEFFREY S. HEIER
- Relationships to issuer
- Officer
- Street
- 14 CROSBY DRIVE, 3RD FLOOR
- City
- BEDFORD
- State / country code
- MA
- Postal code
- 01730
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 10,869 | 76,639.49 | 219,615,868 | 10/02/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2026 | Restricted Stock Vesting Under a Registered Plan | Issuer | 10,869 | N | 10/01/2026 | Not Applicable |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| JEFFREY S. HEIER | Common | 08/24/2026 | 3,296 | 35,532.20 |
Seller — prior-sale row 1, entry 1
- Name
- JEFFREY S. HEIER
- Street
- 15 Crosby Drive
- City
- Bedford
- State / country code
- MA
- Postal code
- 01730
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 10/02/2026
- Signed
- /s/ Jeffrey Heier
Company context
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).